Wegovy
-
{
- All
- News
-
On Ozempic Or Wegovy? Doctors Say Stop Before Surgery, Here's Why
The ASA guidance suggests that patients on GLP-1 drugs should consult their healthcare providers well in advance of any planned surgery.
-
From Ozempic To Bariatric Surgery, Delhi Doctor Ranks 7 Weight-Loss Methods
Not everyone can or should opt for Ozempic, Mounjaro, or bariatric surgery for weight loss. The doctor lists seven methods and explains who they suit best
-
Novo Nordisk Partners With OpenAI To Accelerate Drug Discovery
The company said Artificial Intelligence will be used to analyse complex datasets, identify potential drug candidates and reduce the time taken to move from research to clinical application.
-
Can Using Ozempic Cause Your Hair To Fall Out? Experts Explain
Ozempic can lead to potential thinning of hair strands. Here is what Dr Neha Shah, Dr Sharmatha, Dr Narayanan A, Dr Gaurang Krishna, and Dr Krishna want to convey to the people using Ozempic.
-
With Rs 13,000-25,000 Per Dose, Weight-Loss Drugs Are Changing Indian Weddings For Brides
The lowest Mounjaro injection pen dose sells for Rs 13,125 per month, while the highest dose costs Rs 25,781. Novo is selling the lowest Wegovy dose for Rs 5,660 and the highest for Rs 16,400 a month
-
GLP-1 Should Not Be Used As A Quick Fix For Weight Loss And Diabetes Management, Warns Top Experts
Experts warn that GLP1 drugs like Ozempic and Wegovy aren't quick fixes. There are misuse risks that are involved as shortages, side effects, and weight regain are possible without medical supervision.
-
Higher-Dose Wegovy Gets US Nod, Trials Show Over 20% Average Weight Loss, Says Drugmaker
Novo Nordisk said it plans to launch the new formulation, (semaglutide 7.2 mg), in the United States in April 2026.
-
From Diabetes To Weight Loss: How Semaglutide Became The Blockbuster Behind Ozempic, Wegovy
From a diabetes drug to a global weight-loss phenomenon, semaglutide has reshaped modern medicine. As patents expire, cheaper versions may expand access, raising questions about affordability, safety and long-term impact.
-
Wegovy Users Have 5x Higher Vision Loss Risk Than Ozempic, New Study Finds
A new study found that users of Wegovy have nearly five times the risk of ischemic optic neuropathy (ION), compared to Ozempic users. ION, also known as 'eye stroke', is a condition that happens due to reduced blood flow to the optic nerve.
-
Cheap Generic Ozempic To Hit India: Patent Exit Sparks Weight-Loss Drug Boom
Swati Pradhan sees about 12 obesity patients a day at her clinic in southern Mumbai. She expects this number to at least double from this month as Indian drug makers prepare to launch off-patent versions of Novo Nordisk A/S's blockbuster weight.
-
On Ozempic Or Wegovy? Doctors Say Stop Before Surgery, Here's Why
The ASA guidance suggests that patients on GLP-1 drugs should consult their healthcare providers well in advance of any planned surgery.
-
From Ozempic To Bariatric Surgery, Delhi Doctor Ranks 7 Weight-Loss Methods
Not everyone can or should opt for Ozempic, Mounjaro, or bariatric surgery for weight loss. The doctor lists seven methods and explains who they suit best
-
Novo Nordisk Partners With OpenAI To Accelerate Drug Discovery
The company said Artificial Intelligence will be used to analyse complex datasets, identify potential drug candidates and reduce the time taken to move from research to clinical application.
-
Can Using Ozempic Cause Your Hair To Fall Out? Experts Explain
Ozempic can lead to potential thinning of hair strands. Here is what Dr Neha Shah, Dr Sharmatha, Dr Narayanan A, Dr Gaurang Krishna, and Dr Krishna want to convey to the people using Ozempic.
-
With Rs 13,000-25,000 Per Dose, Weight-Loss Drugs Are Changing Indian Weddings For Brides
The lowest Mounjaro injection pen dose sells for Rs 13,125 per month, while the highest dose costs Rs 25,781. Novo is selling the lowest Wegovy dose for Rs 5,660 and the highest for Rs 16,400 a month
-
GLP-1 Should Not Be Used As A Quick Fix For Weight Loss And Diabetes Management, Warns Top Experts
Experts warn that GLP1 drugs like Ozempic and Wegovy aren't quick fixes. There are misuse risks that are involved as shortages, side effects, and weight regain are possible without medical supervision.
-
Higher-Dose Wegovy Gets US Nod, Trials Show Over 20% Average Weight Loss, Says Drugmaker
Novo Nordisk said it plans to launch the new formulation, (semaglutide 7.2 mg), in the United States in April 2026.
-
From Diabetes To Weight Loss: How Semaglutide Became The Blockbuster Behind Ozempic, Wegovy
From a diabetes drug to a global weight-loss phenomenon, semaglutide has reshaped modern medicine. As patents expire, cheaper versions may expand access, raising questions about affordability, safety and long-term impact.
-
Wegovy Users Have 5x Higher Vision Loss Risk Than Ozempic, New Study Finds
A new study found that users of Wegovy have nearly five times the risk of ischemic optic neuropathy (ION), compared to Ozempic users. ION, also known as 'eye stroke', is a condition that happens due to reduced blood flow to the optic nerve.
-
Cheap Generic Ozempic To Hit India: Patent Exit Sparks Weight-Loss Drug Boom
Swati Pradhan sees about 12 obesity patients a day at her clinic in southern Mumbai. She expects this number to at least double from this month as Indian drug makers prepare to launch off-patent versions of Novo Nordisk A/S's blockbuster weight.
